88 related articles for article (PubMed ID: 23255002)
1. Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells.
Kasukabe T; Okabe-Kado J; Haranosono Y; Kato N; Honma Y
Int J Oncol; 2013 Feb; 42(2):767-75. PubMed ID: 23255002
[TBL] [Abstract][Full Text] [Related]
2. Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells.
Kasukabe T; Okabe-Kado J; Kato N; Honma Y; Kumakura S
Int J Oncol; 2015 Feb; 46(2):841-8. PubMed ID: 25405645
[TBL] [Abstract][Full Text] [Related]
3. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
Roforth MM; Tan C
Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
[TBL] [Abstract][Full Text] [Related]
4. Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts.
Kasukabe T; Okabe-Kado J; Kato N; Sassa T; Honma Y
Breast Cancer Res; 2005; 7(6):R1097-110. PubMed ID: 16457690
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells.
Chen JC; Ko JC; Taso YC; Cheng HH; Chen TY; Yen TC; Lin YW
Pharmacology; 2021; 106(3-4):154-168. PubMed ID: 33202406
[TBL] [Abstract][Full Text] [Related]
6. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
[TBL] [Abstract][Full Text] [Related]
8. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
10. 17-(Allylamino)-17-Demethoxygeldanamycin Enhances Etoposide-Induced Cytotoxicity via the Downregulation of Xeroderma Pigmentosum Complementation Group C Expression in Human Lung Squamous Cell Carcinoma Cells.
Chen JC; Ma PF; Lin YC; Wu CH; Peng YS; Zheng HY; Lin MC; Li YT; Lin YW
Pharmacology; 2018; 102(1-2):91-104. PubMed ID: 29953987
[TBL] [Abstract][Full Text] [Related]
11. 17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways.
Lee KH; Jang AH; Yoo CG
Am J Respir Cell Mol Biol; 2015 Sep; 53(3):412-21. PubMed ID: 25633180
[TBL] [Abstract][Full Text] [Related]
12. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
13. Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2.
Kasukabe T; Okabe-Kado J; Honma Y
Cancer Sci; 2008 Aug; 99(8):1693-8. PubMed ID: 18754885
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
Solit DB; Basso AD; Olshen AB; Scher HI; Rosen N
Cancer Res; 2003 May; 63(9):2139-44. PubMed ID: 12727831
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.
Premkumar DR; Arnold B; Jane EP; Pollack IF
Mol Carcinog; 2006 Jan; 45(1):47-59. PubMed ID: 16267832
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
[TBL] [Abstract][Full Text] [Related]
17. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
Pelicano H; Carew JS; McQueen TJ; Andreeff M; Plunkett W; Keating MJ; Huang P
Leukemia; 2006 Apr; 20(4):610-9. PubMed ID: 16482209
[TBL] [Abstract][Full Text] [Related]
18. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
Takeuchi H; Kondo Y; Fujiwara K; Kanzawa T; Aoki H; Mills GB; Kondo S
Cancer Res; 2005 Apr; 65(8):3336-46. PubMed ID: 15833867
[TBL] [Abstract][Full Text] [Related]
19. Lectin, Galactoside-Binding Soluble 3 Binding Protein Promotes 17-N-Allylamino-17-demethoxygeldanamycin Resistance through PI3K/Akt Pathway in Lung Cancer Cell Line.
Woo JK; Jang JE; Kang JH; Seong JK; Yoon YS; Kim HC; Lee SJ; Oh SH
Mol Cancer Ther; 2017 Jul; 16(7):1355-1365. PubMed ID: 28336809
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]